whitepaper
MEA to probe ALS phenotypes in neuronal disease models
Explore an MEA workflow used to validate the ALS-relevant phenotype of precision reprogrammed iPSC-derived neuronal disease models of ALS from bit.bio
List view / Grid view
bit.bio
whitepaper
Consistent, functional lower motor neurons from iPSCs
How pure consistent and functional lower motor neurons can be precision reprogrammed from iPSCs for motor neuron disease research and drug discovery.
whitepaper
Application note: Developing next-gen in vitro Huntington’s disease assays
The use of high-density MEAs to probe single cell and network activity electrophysiology of a hiPSC-derived Huntington’s disease model
whitepaper
Infographic: Differentiating iPSCs – Which approach works best?
Download this infographic to find out why the method of generating human iPSC-derived cells matters.
whitepaper
Product hub: A reproducible and scalable Huntington’s disease human cell model
Senior scientist Dr Tony Oosterveen discusses bit.bio’s new ioDisease Model portfolio, including new models for Huntington’s disease to help advance in vitro research and drug discovery.
news
bit.bio raises $103 million in first close of Series B financing
The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.